Human and Microbial Integrative Genomics

Human and Microbial Integrative Genomics


Advances in human and microbial genomics are already playing a profound role in medicine. The development of new bioinformatics tools is needed for the integration of data across multiple "omics" (genomics, metagenomics, metabolomics, proteomics, etc.), which is essential to decipher the etiology and mechanisms underpinning complex systems such as cancers, infectious and inflammatory diseases. Clearly,  our  research  program  addresses  biological  questions  of  paramount  importance  to  human health. The infrastructure requested is crucial to achieve our multidisciplinary projects, all linked by the critical   need   for   integrative   genomics,   including   a   substantial   investment   for   resources   in bioinformatics. Through prior CFI/Qc investments, our group has acquired genomic, proteomic, metabolomic and mass spectrometry infrastructuresthat enabled highly competitive research to beconducted and for which substantial return on investment has been delivered.

We are now requesting gold-standard equipment clusters to support high-throughput investigations consisting of next- generation DNA sequencers (HiSeq2500 sequencer and upgrades), mass spectrometers for protein and metabolite analyses (LTQ-Orbitrap, Qtrap5500 and Qexactive) as well as computerprocessing hardware. These complementary and interconnected infrastructures in line with the established and unique expertise of our group, will provide the basis for conducting human and microbial research programs in 3 key aspects of human and microbial genomics: i) genetic architecture of disease susceptibility and pathogenesis; ii) biomarker discovery in disease diagnosis, prognosis and treatment; and iii) novel drug target discovery and characterization. Major breakthroughs will be translated into a more predictive, preventive and personalized approach to health leading to precise and rapid diagnoses, treatments tailored to individual, reduction inadverse reactions to drugs, breakthroughs in treatment and ultimately prevention of major chronic and infectious diseases. However, their scientific excellence no longer suffices to support a national and dynamic life-science sector and maintaining state-of-the-art instrumentations is essential. The requested infrastructure is thus timely and will sustain, profoundly improve and greatly enhance the development of well-funded innovative health research programs and those  of  promising  younger  scientists  that  are  crucially  dependent  on  the  unique  combination  of genome, metabolome and proteome studies supported by computational biology.

Investigators


Jacques Simard

CHUdeQc/Université Laval

Jacques Corbeil

CHUdeQc/Université Laval

Michel G. Bergeron

CHUdeQc/Université Laval

Olivier Barbier

Université Laval

Arnaut Droit

CHUdeQc/Université Laval

Francine Durocher

CHUdeQc/Université Laval

Chantale Guillemette

CHUdeQc/Université Laval

Marc Ouellet

CHUdeQc/Université Laval

Barbara Papadopoulou

CHUdeQc/Université Laval

Guy Poirier

CHUdeQc/Université Laval

 

 

 

 

Funding


INN_CFI_ENB_2C_RGB